The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.
The partnership provides clinical and pathology laboratories that have adopted Cartagenia’s Bench for Oncology software platform for their genetic sequencing analysis and reporting workflow with the option to
To support and advance this molecule, Encycle Therapeutics is collaboratively partnering with the Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR), the Université de
The portfolio includes leading brands built by strong levels of professional recommendations which have demonstrated excellent growth potential. The brands Lipo-Flavonoid®, Certain Dri®, Cystex®, Albolene, Absorbine Jr.®, and
If successful, the company could then move forward with medical research investigating whether or not the product is efficacious in areas like cancer, post-traumatic stress disorder, concussions, epilepsy,
Evolocumab inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol (LDL-C) or bad cholesterol from the blood. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
